key: cord-0715801-ufgl0qu7
authors: Motozono, Chihiro; Toyoda, Mako; Zahradnik, Jiri; Saito, Akatsuki; Nasser, Hesham; Tan, Toong Seng; Ngare, Isaac; Kimura, Izumi; Uriu, Keiya; Kosugi, Yusuke; Yue, Yuan; Shimizu, Ryo; Ito, Jumpei; Torii, Shiho; Yonekawa, Akiko; Shimono, Nobuyuki; Nagasaki, Yoji; Minami, Rumi; Toya, Takashi; Sekiya, Noritaka; Fukuhara, Takasuke; Matsuura, Yoshiharu; Schreiber, Gideon; Ikeda, Terumasa; Nakagawa, So; Ueno, Takamasa; Sato, Kei
title: SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
date: 2021-06-15
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.06.006
sha: 9d90e42032403f9c1f6b6cb6d5ec5308d2124a1f
doc_id: 715801
cord_uid: ufgl0qu7

Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These mutations can affect viral properties such as infectivity and immune resistance. Although the sensitivity of naturally occurring SARS-CoV-2 variants to humoral immunity has been investigated, sensitivity to human leukocyte antigen (HLA)-restricted cellular immunity remains largely unexplored. Here, we demonstrate that two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R (in B.1.427/429 and B.1.617) and Y453F (in B.1.1.298), confer escape from HLA-A24-restricted cellular immunity. These mutations reinforce affinity toward the host entry receptor ACE2. Notably, the L452R mutation increases spike stability, viral infectivity, viral fusogenicity, and thereby promotes viral replication. These data suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes and that a further threat of the SARS-CoV-2 pandemic is escape from cellular immunity.

The emergence of mutated viruses is mainly due to error-prone viral 118 replication, and the spread of emerged variants can be attributed to the escape 119 from immune selective pressures [ In addition to the humoral immunity mediated by neutralizing antibodies, 129

another protection system against pathogens is the cellular immunity due to In this study, we investigated the possibility of the emergence of 143 SARS-CoV-2 mutants that are able to escape HLA-restricted cellular immunity. We 144 demonstrate that at least two naturally occurring substitutions in the 145 receptor-binding motif (RBM; residues 438-506) of the SARS-CoV-2 S protein, 146 L452R and Y453F, which were identified in the two major variants, B.1.427/429 147 (L452R) and B1.1.298 (Y453F), can be resistant to cellular immunity in the context 148 of HLA-A24, an allele of HLA-I. More intriguingly, the L452R and Y453F mutants 149 enhance binding affinity for ACE2, and experiments using pseudoviruses show that 150 the L452R substitution increases viral infectivity. Furthermore, we artificially 151 generated SARS-CoV-2 harboring these point mutations by reverse genetics and 152

show that the L452R mutant enhances viral replication capacity. 153

Evasion from HLA-A24-restricted CTL responses by acquisition of mutations  155 in the RBM of the SARS-CoV-2 S protein 156 We set out to address the possibility of the emergence of naturally occurring 157 mutants that can confer resistance to antigen recognition by HLA-restricted cellular 158 immunity. A bioinformatic study has suggested that the 9-mer peptide in the RBM, 159 NYNYLYRLF (we designate this peptide "NF9"), which spans 448-456 of the S 160 protein, is the potential epitope presented by HLA-A24 (Kiyotani et al., 2020), an 161

HLA-I allele widely distributed globally and particularly predominant in East and 162

Southeast Asian areas ( with HLA-A*24:02 and stimulated these cells with the NF9 peptide ( Table S2) . As 168 shown in Figure 1A , two activation markers, CD25 and CD137, were upregulated in 169 a fraction of CD8 + T cells in response to stimulation with NF9. In the sixteen 170 samples of the CD8 + T cells from COVID-19 convalescent patients with 171

HLA-A*24:02, the percentage of CD25 + CD137 + cells in the presence of the NF9 172 peptide (median 5.2%) was significantly higher than that in its absence (median 173 0.44%) ( Figure 1B ; P = 0.0003 by Wilcoxon signed-rank test). In contrast, 174 stimulation with the NF9 peptide did not upregulate CD25 and CD137 on the CD8 + 175

T cells of three seronegative samples with HLA-A*24:02, and the percentage of 176 CD25 + CD137 + cells in seronegative samples (median 0.93%) was significantly 177 lower than that in COVID-19 convalescent samples ( Figure 1B ; P = 0.0003 by 178

Wilcoxon signed rank test). We also verified that the NF9 peptide did not activate 179 the CD8 + T cells in six COVID-19 convalescent samples with non-HLA-A24 (median peptide is an immunodominant HLA-A*24:02-restricted epitope recognized by the 184 CD8 + T cells of COVID-19 convalescents in our cohort. In particular, a convalescent 185 sample from donor #13 exhibited a prominent CD8 + T cell-mediated response 186 triggered by the NF9 peptide ( Figure 1B and Table S2) . Notably, the PBMCs of 187 donor #13 were collected 68 days after PCR positivity ( Table S2) , suggesting that 188 NF9-mediated CD8 + T cell immunity can be maintained for a relatively long period 189 and that NF9 is an important epitope. 190 J o u r n a l P r e -p r o o f

We then assessed the profile of cytokine production by NF9 stimulation. 191 As depicted in Figure 1C , stimulation with the NF9 peptide induced the production  192  of IFN-γ, TNF-α and IL-2 by the CD8 + T cells from a COVID-19 convalescent patient.  193 According to analysis using eight COVID-19 convalescent samples, the CD8 + T 194 cells produced multiple cytokines in response to NF9 stimulation ( Figure 1D) , 195 demonstrating the multifunctional nature of NF9-specific CD8 + T cells of COVID-19 196 convalescent patients. Moreover, the cytotoxic potential of NF9-specific CD8 + T 197 cells was assessed by staining with surface CD107a, a degranulation marker 198 ( Figure 1E ). As shown in Figure 1F , HLA-A24, and four out of the five tools predicted that the Y453F mutation 218 decreases the binding affinity ( Figure S1A ).

To experimentally address the possibility that these naturally occurring 220 mutations, L452R and Y453F in the NF9 region, confer evasion ability from 221 NF9-specific CD8 + T cells in HLA-A24-positive COVID-19 convalescents, two NF9 222 derivatives containing either substitution (NF9-L452R and NF9-Y453F) were 223 prepared and used for stimulation experiments. As shown in Figure S1B , parental 224 NF9 induced IFN-γ expression in a dose-dependent manner. In contrast, the level 225 of IFN-γ expression induction by the NF9-Y453F derivative was significantly lower 226 than that by parental NF9, and intriguingly, the NF9-L452R derivative did not induce 227 IFN-γ expression, even at the highest concentration tested (10 nM) ( Figure S1C) . 228 J o u r n a l P r e -p r o o f Among the eight HLA-A24-positive COVID-19 convalescent samples tested,  229  parental NF9 peptide significantly induced IFN-γ expression. In contrast, the  230  NF9-L452R derivative did not activate all CD8 + T cells tested, and seven out of the  231  eight HLA-A24-positive COVID-19 convalescent samples failed to be activated by  232 the NF9-Y453F derivative (Figures 1H and 1I) Figure 2D ).

Increase in pseudovirus infectivity by the L452R mutation 261

To directly analyze the effect of these mutations on viral infectivity, we prepared an 262

HIV-1-based reporter virus pseudotyped with the SARS-CoV-2 S protein and its 263 mutants as well as HEK293 cells transiently expressing human ACE2 and 264

TMPRSS2. As shown in Figure 2E , although the N501Y mutation slightly affected 265 viral infectivity in this assay, the L452R mutation significantly increased it compared 266 J o u r n a l P r e -p r o o f to the parental S protein. In contrast to the yeast display assay (Figures 2B and  267 2C), the infectivity of the Y453F mutant was significantly lower than that of the 268 parental S protein ( Figure 2E ). Similar to the observations using human ACE2 269 (Figure 2E) , the L452R mutant but not the other mutants including the Y453F 270 mutant significantly increased infection efficacy using mink ACE2 as the receptor 271 ( Figure S1D) . Moreover, we demonstrated that the infectivity of the reporter virus 272 pseudotyped with the S protein of the B.1.429 variant, which harbors the L452R 273 mutation, was significantly higher than those of parental S as well as the 274 D614G-harboring S, while that of the B.1.1.298 variant, which harbors the Y453F 275 mutation, was not ( Figure 2F) . Altogether, these findings suggest that the L452R 276 substitution increases the binding affinity of the SARS-CoV-2 RBD toward human 277 ACE2, protein stability, and viral infectivity. Although the L452 residue is not directly 278 located at the binding interface ( indicating that strain WK-521 is a SARS-CoV-2 prototype. We verified insertion of 295 the targeted mutations in the viruses generated by direct sequencing (Figure 2H ) 296 and performed virus replication assays using these recombinant viruses. As shown 297

in Figure 2I , the cytotoxicity of the L452R mutant was higher than that of the other 298 mutants and the parental virus. We also found that the growth rates of the L452R 299 mutant in VeroE6/TMPRSS2 cells (Figure 2J ), HEK293 cells stably expressing 300 human ACE2 (HEK293-ACE2; Figure 2K ) and A549 cells stably expressing human 301 ACE2 (A549-ACE2; Figure 2L ) were significantly higher than those of the parental 302

virus. The predominance of the L452R mutant was observed at different doses 303 ( Figure S1E ). Moreover, a competition assay using the parental virus and the 304 J o u r n a l P r e -p r o o f L452R mutant showed that the L452R mutant expanded more predominantly than 305 the parental virus ( Figure 2M ). Together with the results of the binding assay 306 (Figures 2B-2D ) and the assay using pseudoviruses (Figures 2E-2F and S1E), our 307 results suggest that the L452R mutation promotes viral replication. 308 309

Increase in viral fusogenicity by the L452R mutation 310 We next tested how the L452R mutation increases viral infectivity and cytotoxicity 311 by performing a SARS-CoV-2 S-based fusion assay. As shown in Figure S1F , the 312 surface expression levels of parental S and its derivatives on effector cells were 313

comparable. Using the SARS-CoV-2 S-based fusion assay, we demonstrated that 314 the L452R mutation significantly increased fusion efficacy compared to the parental 315 S, as well as the other mutants ( Figure 2N ). Our data suggest that the L452R 316 mutation promotes viral replication by increasing viral fusogenicity. 317 318

Dynamics of the spread of RBM mutants during the current pandemic 319 We finally assessed the epidemic dynamics of naturally occurring variants 320

containing the L452 and Y453 substitutions. The L452R mutants were mainly found 321

(3,967 sequences) in the B. Quintana Roo state, Mexico, on July 6, 2020 (GISAID ID: EPI_ISL_942929) (Table  327 1), and L452R-harboring mutants were first collected in California, USA, on 328

September 28, 2020 (GISAID ID: EPI_ISL_730092 and EPI_ISL_730345) ( Table S5 ).

Regarding the Y453F mutation, 1,274 of the 1,380 mutated sequences 334 belong to the B.1.1.298 lineage, which has been exclusively detected in Denmark 335

( Table S4 ). The oldest sequence in the B.1.1.298 lineage that contains the Y453F 336 mutation was isolated from a human in Denmark on April 20, 2020 (GISAID ID: 337 EPI_ISL_714253) ( Figure 3C) . Intriguingly, the B.1.1.298 variants containing either 338 Y453 or F453 were detected not only in humans but also in minks ( Figure 3D ). 339

Phylogenetic analysis of the entire genome sequences of the B.1.1.298 lineage 340

suggested multiple SARS-CoV-2 transmissions between humans and minks 341 ( Figure S2) . Additionally, the three sequences that contain the Y453F mutation 342 J o u r n a l P r e -p r o o f were isolated from cats in Denmark: two identical sequences (GISAID ID: 343 EPI_ISL_683164 and EPI_ISL_683166) and another sequence (GISAID ID: 344 EPI_ISL_683165) of a distinct origin ( Figure S2 ). These results suggest that this 345 SARS-CoV-2 variant has transmitted from humans to cats multiple times and that 346 some of them may have spread among the Danish cat population. Nevertheless, 347

the epidemic of a fraction of the B.1.1.298 lineage containing the Y453F mutation in 348

Denmark peaked from October to November 2020 and then gradually declined 349

( Figure 3D ). The variant containing the Y453F mutation was last collected in 350

Denmark on January 18, 2021 (GISAID ID: EPI_ISL_925998), and it has not been 351

reported worldwide since ( Figure 3D ). 352

In the present study, we demonstrate that at least two naturally occurring mutations 354

in the SARS-CoV-2 RBM, L452R and Y453F, escape HLA-restricted cellular 355

immunity and further promote affinity toward the viral receptor ACE2. We also 356 demonstrate that the L452R mutation increases the stability of the S protein and 357 viral infectivity and thereby enhances viral replication. Our data suggest that the 358 L452R mutant escapes HLA-A24-restricted cellular immunity and further 359 strengthens its infectivity. All authors reviewed and proofread the manuscript. 515

The Genotype to Phenotype Japan (G2P-Japan) Consortium contributed to the 516 project administration. 517 518

Consortia 519

The Genotype to Phenotype Japan (G2P-Japan University of Tokyo, Japan) for providing plasmids, reagents and cells. The 536

super-computing resource was provided by Human Genome Center at The 537

University of Tokyo and the NIG supercomputer at ROIS National Institute of 538

Genetics. 539

This study was supported in part by AMED Research Program on 540

Emerging and Re-emerging Infectious Diseases 20fk0108163 (to A.S.), 541

20fk0108539 ( See also Figure S1 and Tables S1-S3. 

J o u r n a l P r e -p r o o f One-Glo luciferase assay system Promega Cat# E6130

Functional and genetic analysis of viral receptor ACE2 orthologs 726 reveals a broad potential host range of SARS-CoV-2

Neutralizing activity of 729 BNT162b2-elicited serum

Identification of 732 SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody 733 neutralization

NetMHC-3.0: accurate web accessible predictions of human, mouse and 736 monkey MHC class I affinities for peptides of length 8-11

Assessing the SARS-CoV-2 threat to wildlife: Potential risk to a broad range of 741 mammals

Enhanced isolation of 744 SARS-CoV-2 by TMPRSS2-expressing cells

Recurrent deletions in the SARS-CoV-2 spike 748 glycoprotein drive antibody escape

The B1.351 and P.1 751 variants extend SARS-CoV-2 host range to mice

Sequence-based HLA-A

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

In vivo gene delivery and stable transduction of nondividing 762 cells by a lentiviral vector

SARS-CoV-2-derived peptides 765 define heterologous and COVID-19-induced T cell recognition

Reliable prediction of T-cell epitopes using neural 769 networks with novel sequence representations

Efficient selection for 771 high-expression transfectants with a novel eukaryotic vector

Infection with SARS-CoV-2 in animals

Transmission of SARS-CoV-2 on mink farms between humans and mink 777 and back to humans

SARS-CoV-2 D614G spike mutation 780 increases entry efficiency with enhanced ACE2-binding affinity

Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide 784 tag

Cross-species virus transmission 787 and the emergence of new epidemic diseases

Application of the restriction-free (RF) cloning for 789 multicomponents assembly

UCSF Chimera-A visualization system for 792 exploratory research and analysis

Spike mutation D614G 795 alters SARS-CoV-2 fitness

The variant ambit: COVID's next move

800 sequences by using the FFT-NS-2 program in MAFFT suite v7

We selected GTR+I as the best-fit 1130 nucleotide substitution model using ModelTest-NG v0

Based on this model, we generated a maximum-likelihood-based phylogenetic tree 1132 using RAxML-NG

After incubation 1144 at 37°C for 1 h, the cells were washed, and surface proteins (CD3, CD8, CD14, 1145 CD19, CD25 and CD137) were stained with the antibodies listed in Key Resources 1146 Table. Dead cells were stained with 7-aminoactinomycin D (Biolegend, cat# 1147 420404). After incubation for 20 min on ice, the cells were fixed with 1% 1148 paraformaldehyde (Nacalai Tesque, cat# 09154-85), and the levels of protein 1149 surface expression were analyzed by flow cytometry using a FACS Canto II

Y6F in NF9); synthesized by Scrum Inc.] at concentrations from 0.1 1157 to 10 nM at 37°C for 1 h. The cells were washed twice with PBS, mixed with the 1158 CTL lines generated from COVID-19 convalescent samples (see above) and 1159 incubated with RPMI 1640 medium (Thermo Fisher Scientific, cat# 11875101) 1160 containin 10% FCS, 5 μ /ml brefeldin A (Si ma-Aldrich, cat# B7651), 2 μM 1161 monensin (Biolegend, cat# 420701) and a BV421-anti-CD107a antibody (Biolegend, 1162 cat# 420404) in a 96-well U plate at 37°C for 5 h

TGC 1192

GCA-3'; and S HV69-70del reverse, 5'-TGC 1199 CAT TGG TGC CAG AGA TGG CAT GGA ACC-3'. The resulting PCR fragment 1200 was digested with KpnI and NotI and inserted into the KpnI-NotI site of the pCAGGS 1201 vector

The fluorescent signal was 1280 processed as previously described (Zahradník et al., 2021b), and the standard 1281 noncooperative Hill equation was fitted by nonlinear least-squares regression using 1282 Python

and 500 ng of plasmids expressing 1289 parental S or its derivatives (L452R, Y453F, N501Y, D614G, B.1.429 and 1290 B.1.1.298) using Lipofectamine 3000 (Thermo Fisher Scientific, cat# L3000015) 1291 according to the manufacturer's protocol. At two days posttransfection, the culture 1292 supernatants were harvested, centrifuged, and treated with 37.5 U/ml DNase I 1293 (Sigma-Aldrich, cat# 11284932001) at 37°C for 30 min. The amount of 1294 pseudoviruses prepared was quantified using the HiBiT assay, and the measured 1295 value was normalized to the level of HIV-1 p24 antigen as previously described 1296

Briefly, the VSV-G-pseudotyped lentivirus vector 1311 expressing human ACE2 as enerated by transfectin 2.5 μ of pLV-EF1a-human 1312 ACE2-IRES-Puro plasmid with 1.67 μ of pΔ-NRF (expressing HIV-1 gag, pol, rev, 1313 and tat genes

At two days 1316 posttransfection, the culture supernatants were harvested and centrifuged, and the 1317 supernatants were filtered with a 0.45-µm pore size filter (Millipore, cat# 1318 SLGVR33RB) and collected as the lentiviral vector. The lentivirus vectors were 1319 concentrated by centrifugation (at 22,000 × g for 2 h at 4°C), and the concentrated 1320 vectors were inoculated into target cells (HEK293 cells and A549 cells) and 1321 incubated at 37°C

A goat 1326 anti-ACE2 polyclonal antibody (R&D Systems, cat# AF933) and an APC-conjugated 1327 donkey anti-goat IgG (R&D Systems, cat# F0108) were used for surface ACE2 1328 staining. Normal goat IgG (R&D Systems, cat# AB-108-C) was used as the 1329 negative control for this assay

Reverse Genetics 1339 Recombinant SARS-CoV-2 was generated by circular polymerase extension 1340 reaction (CPER) as previously described (Torii et al., 2021). In brief, 9 DNA 1341 fragments encoding the partial genome of SARS-CoV-2 (strain

A linker fragment 1344 encoding hepatitis delta virus ribozyme (HDVr), bovine growth hormone (BGH) 1345 polyA signal and cytomegalovirus (CMV) promoter was also prepared by PCR. The 1346 corresponding SARS-CoV-2 genomic region and the templates and primers of this 1347 PCR are summarized in Table S6. The 10 obtained DNA fragments were mixed 1348 and used for CPER

Nucleotide sequences were sample (2.5 μl) as used as the template for real-time RT-PCR performed 1431 accordin to the manufacturer's protocol usin the One Step TB reen PrimeScript 1432 PLUS RT-PCR kit (Takara, cat# RR096A) and the following primers: Forward N, 1433 5'-AGC CTC TTC TCG TTC CTC ATC AC-3'; and Reverse N, 5'-CCG CCA TTG 1434 CCA GCC ATT C-3'. The copy number of viral RNA was standardized with a 1435 SARS-CoV-2 direct detection RT-qPCR kit (Takara, cat# RC300A). The fluorescent 1436 signal was acquired using a QuantStudio 3 Real-Time PCR system

Competition Assay 1441 One day prior to infection, 100,000 HEK293-ACE2 cells were seeded into 12-well 1442 plates. Parental virus and the L452R mutant were mixed at a 1:1 ratio based on the 1443 PFU. The virus mixture was inoculated at a final concentration of 1,000 PFU (i.e., 1444 500 PFU for each virus) and incubated at 37°C for 1 h. The infected cells were 1445 washed, and 1 ml of culture medium was added. The culture supernatant (140 µl) 1446 was harvested at the indicated time points

Viral RNAs were isolated from the harvested culture supernatant using a QIAamp 1448 viral RNA mini kit (QIAGEN, cat# 52906), and cDNA was synthesized using reverse 1449 transcriptase (Roche, cat# 03531317001) with a random hexamer

CAG GGC AAA 1451 CTG GAA AGA TT-3' and reverse, 5'-TCA GCA ATG TCT CTG CCA AA-3'). The 1452 PCR products were purified using a GeneJET gel extraction kit (Thermo Fisher 1453 Scientific, cat# K0692) and subjected to Sanger sequencing with the following 1454 primer: 5'-CAG GGC AAA CTG GAA AGA TT-3'. The nucleotide variation at 1455 position

2011) with 1461 some modifications. This assay utilizes a dual split protein (DSP) encoding Renilla 1462 luciferase (RL) and GFP genes, and the respective split proteins, DSP 1-7 and 1463 DSP 8-11 , are expressed in effector and target cells by transfection

On day 4 (72 h posttransfection), target 1476 cells were incubated with EnduRen live cell substrate (Promega, cat# E6481) for 1477 three hours and then detached, and 32,000 target cells were applied to a 96-well 1478 plate with effector cells. RL activity was measured at the indicated time points by 1479 using a Centro XS3 LB960 (Berthhold Technologies). The S proteins expressed on 1480 the surface of effector cells were stained with a rabbit anti-SARS-CoV-2 monoclonal 1481 antibody (GeneTex, cat# GTX635654) and an APC-conjugated goat anti-rabbit IgG 1482

In Figures 1B 1490 and 1F, data are presented as median with SD, and n represents the number of 1491 PBMC donor. In the other figure panels, data are presented as average with SD, 1492 and n represents the number of technical replicate

In Figure 1I, statistically significant differences are determined by ANOVA, with 1495 multiple comparisons by Bonferroni correction. In Figure 2C, statistically significant 1496 difference are determined by the Mann-Whitney U test

APC-Cy7-conjugated anti-human CD8 antibody Biolegend Cat# 301016

5-conjugated anti-human CD14 antibody Biolegend Cat# 325622

5-conjugated anti-human CD19 antibody Biolegend Cat# 302230

PE-Cy7-conjugated anti-human CD25 antibody Biolegend Cat# 356107

APC-conjugated anti-human CD137 antibody Biolegend Cat# 309809; RRID: AB_830671 BV421-conjugated anti-human CD107a antibody Biolegend Cat# 328625

PE-conjugated anti-human IFN-γ antibody BD

PE-Cy7-conjugated anti-human TNF-α antibody Biolegend Cat# 502930

APC-conjugated anti-human IL-2 antibody Biolegend Cat# 500310

APC-conjugated anti-goat IgG R&D Systems Cat# F0108; RRID: AB_573124 Goat normal IgG R&D Systems Cat# AB-108-C

Anti-SARS-CoV-2 S antibody GeneTex Cat# GTX635654

APC-conjugated anti-rabbit IgG Jackson ImmunoResearch Cat#

Plasmid: template plasmids for the preparation of the partial SARS-CoV-2 genome fragments for CPER, see Table S6

target cells (ACE2-expressing cells) were prepared, and the fusion activity was 1009 measured as described in STAR★METHODS. Assays were performed in 1010 quadruplicate, and fusion activity (arbitrary unit) is shown. 1011In C, statistically significant differences (*, P < 0.05) versus parental S are 1012 determined by the Mann-Whitney U test. 1013 In E and F, statistically significant differences (*, P < 0.05) versus parental S (E) 1014 and the D614G mutant (F) at the same dose were determined by Student's t test. 1015In J-L and N, statistically significant differences (*, P < 0.05) versus parental virus 1016 (J-L) or parental S (N) were determined by Student's t test. 1017In M, values at respective time points were compared with those at the last time 1018 point using a two-tailed, paired Student's t test, and an asterisk denotes familywise 1019 error rate < 0.05 using the Holm test. 1020See also Figure S1 . 1021 The pJYDC1-based yeast display plasmids expressing SARS-CoV-2 RBD and its 1264 mutants were transformed into yeast (Saccharomyces cerevisiae; strain EBY100, 1265ATCC MYA-4941) and selected by growth on SD-W plates (Peleg and Unger, 2014 To generate recombinant SARS-CoV-2 mutants, mutations were inserted 1368 in fragment 8 (Table S6) CTG TAT GGT  1379  TGG TAA CCA ACA CCA TAA GTG GGT TGG AAA CCA TAT GAT TG-3',  1380 accordin to the manufacturer's protocol. Nucleotide sequences were determined 1381 by a DNA sequencing service (Fasmac), and the sequence data were analyzed by 1382Sequencher version 5.1 software (Gene Codes Corporation). The CPER for the 1383 preparation of SARS-CoV-2 mutants was performed using mutated fragment 8 1384 instead of parental fragment 8. Subsequent experimental procedures correspond to 1385 the procedure for parental SARS-CoV-2 preparation (described above). To verify 1386insertion of the mutation in the working viruses, viral RNA was extracted using a 1387QIAamp viral RNA mini kit (Qiagen, cat# 52906) and reverse transcribed using 1388SuperScript III reverse transcriptase (Thermo Fisher Scientific, cat# 18080085) 1389according to the manufacturers' protocols. DNA fragments including the mutations 1390 inserted were obtained by RT-PCR using PrimeSTAR GXL DNA polymerase 1391 (Takara, cat# R050A) and the following primers: WK-521 22607-22630 forward: 1392 determined as described above, and sequence chromatograms ( Figure 2H) One day prior to infection, 10,000 HEK293-ACE2, A549-ACE2 and 1417VeroE6/TMPRSS2 cells were seeded into a 96-well plate. Recombinant 1418 SARS-CoV-2 (10, 100 or 1,000 PFU) was inoculated and incubated at 37°C for 1 h. 1419The infected cells were washed, and 180 µl of culture medium was added. The 1420 culture supernatant (10 µl) was harvested at indicated time points and used for 1421 real-time RT-PCR to quantify the viral RNA copy number. 1422 1423Real-Time RT-PCR 1424The amount of viral RNA in culture supernatant was quantified by real-time RT-PCR 1425 as previously described (Shema Mugisha et